MINUTES

Meeting of the Board of Trustees
of the Medical University of South Carolina

February 9, 2007

It is understood that the Minutes herein recorded have not as yet been approved and cannot be considered as official action of the Board until such approval has been given.

Colcock Hall
Medical University of South Carolina
Charleston, South Carolina
MINUTES  
MEDICAL UNIVERSITY OF SOUTH CAROLINA  
BOARD OF TRUSTEES MEETING  
February 9, 2007

The Board of Trustees of the Medical University of South Carolina convened Friday, February 9, 2007, with the following members present: Dr. Charles B. Thomas, Jr., Chairman; Mr. Thomas L. Stephenson, Esquire, Vice Chairman; Dr. Stanley C. Baker, Jr.; Mr. Melvyn Berlinsky; Mr. William H. Bingham, Sr.; Dr. Cotesworth P. Fishburne, Jr.; Mr. William B. Hewitt; Dr. Donald R. Johnson II; Dr. Paula E. Orr; Dr. E. Conyers O’Bryan, Jr.; Dr. Thomas C. Rowland, Jr.; Mr. Charles W. Schulze; The Honorable Robin M. Tallon; Dr. James E. Wiseman, Jr.; Mr. Allan E. Stalvey, Emeritus.

The following administrative officials were present: Dr. Raymond S. Greenberg, President; Dr. John Raymond, Vice President for Academic Affairs and Provost; Dr. Jerry Reves, Vice President for Medical Affairs, and Dean, College of Medicine; Mr. Stuart Smith, Vice President for Clinical Operations and Executive Director, MUHA; Mr. Jim Fisher, Vice President for Development and Dr. Frank Clark, Vice President for Information Technology and CIO.

The following deans were present: Dr. Jack Sanders, College of Dental Medicine; Dr. Becki Trickey, Interim Dean - the College of Health Professions; Dr. Jerry Reves, College of Medicine; Dr. Gail Stuart, College of Nursing; and Dr. Arnold Karig, College of Pharmacy.

Item 1. Call to Order-Roll Call.

There being a quorum present, Chairman Johnson called the meeting to order at 9:45 a.m. Ms. Celeste Jordan called the roll.

Item 2. Secretary to Report Date of Next Meeting.

The date of the next regularly scheduled meeting is Friday, April 13, 2007.

Item 3. Approval of Minutes of the Regular Meeting of the Medical University of South Carolina Board of Trustees of December 8, 2006.

Board Action: It was moved that the Minutes be approved. The motion was seconded, voted on and unanimously carried.

RECOMMENDATIONS AND INFORMATIONAL REPORTS OF THE PRESIDENT.

OLD BUSINESS: None.

NEW BUSINESS:


Dr. Greenberg stated that there is a new photographic display of the Board Members in the lobby and distributed copies of the display to the members. The January issue of SC Business, which is a publication of the SC Chamber of Commerce, focuses on the competitiveness agenda of the State of SC. Dr. Greenberg distributed a copy to
the members. The publication features Argolyn Bioscience which is one of our spin-off companies founded by Dr. Thomas Dix.

Dr. Greenberg distributed a copy of his activities since the last Board meeting. Everything seems to be moving in the right direction and the team is working well together.

Dean Reves introduced Dr. Amy Blue who is the Director of the Quality Enhancement Plan (QEP) which is an essential component of the University’s SACS reaffirmation of accreditation process. Dr. Blue provided an executive summary of the University’s QEP which focuses on inter-professional education and has been entitled Creating Collaborative Care.

Dr. Greenberg recognized Dr. Tom Higerd, the Associate Provost for Institutional Research and Assessment, who has been working with a large team on campus to put the plan together. The SACS reaccreditation process is going well and the SACS on-site team will visit the campus prior to the April Board meeting. Dr. Greenberg asked for the Board to approve the University’s Quality Enhancement Plan.

**Recommendations of Administration:** That the Quality Enhancement Plan be approved.

**Board Action:** Dr. Thomas made a motion that the Quality Enhancement Plan be approved as presented. The motion was seconded, voted and unanimously approved.

**Item 5. Other Business:** None.

**RESEARCH AND INSTITUTIONAL ADVANCEMENT COMMITTEE. CHAIRMAN: Dr. Cotesworth P. Fishburne, Jr.** (Detailed committee minutes are attached to these minutes).

**OLD BUSINESS:** None.

**NEW BUSINESS:**

**Item 6. General Report of the Associate Provost for Research.**

**Statement:** Dr. Fishburne asked for a round of applause for the work that Dr. Raymond has done as Associate Provost for Research as well as a welcome for the Dr. Steve Lanier, the new Associate Provost for Research.

Dr. Fishburne said that Dr. Lanier had reported to committee that the year-to-date total dollars awarded for research in FY 2007 are slightly ahead of the same period for the previous two fiscal years. Dr. Lanier reported there are two major initiatives underway: one, the NIH Clinical and Translational Science Award proposal which
involves ongoing discussions with USC and the Medical College of Georgia as potential partners and two, a National Science Foundation Research Infrastructure Initiative proposal which emphasizes statewide collaborative activities with Clemson and USC with a focus on computational sciences.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.


Statement: Dr. Fishburne reported that Mr. Jim Fisher reported to Committee that development and fundraising commitments through December 2006, total more than $30 million. The Capital Campaign continues to make progress with more than $88 million raised towards the $300 million goal. At the next Board meeting, Mr. Fisher will present the specifics of the Campaign plan.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.


Statement: Dr. Fishburne stated that Mr. Tom Anderson reported to Committee that the Foundation’s return on investment was 12.2% for the 2006 calendar year. The Foundation assets now total more than $255 million.

Recommendation of Administration: That the report be received as information.

Recommendation of Committee: That the report be received as information.

Board Action: Received as information.

Item 9. Other Committee Business.


Statement: Dr. Fishburne said Mr. Chip Hood reported to Committee that the Foundation is negotiating with a very large pharmaceutical company for a deal which could amount to almost $1 million in associated research support.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.
Board Action: Received as information.

Faculty Presentations.

Statement: Dr. Fishburne reported that Dr. James Norris and Dr. Michael Nishimura made presentations to the Committee. He commented that the presentations were enlightening. He urged all the Board members to attend the Research Committee.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.

Dr. Thomas informed those present that Dr. Fishburne’s wife would have an organ performance at St. Luke’s Chapel on Tuesday at noon and encouraged those in town to attend.

EDUCATION, FACULTY AND STUDENT AFFAIRS COMMITTEE. CHAIRMAN: MR. MELVYN BERLINSKY. (Detailed committee minutes are attached to these minutes).

OLD BUSINESS: None.

NEW BUSINESS:

Item 10. General Report of the Vice President for Academic Affairs and Provost.

Statement: Mr. Berlinsky stated that the Education meeting on Thursday was superb and thanked Dr. Raymond for having the student presentations during Committee. Dr. Raymond said Dr. West organized it and he agreed the student presentations were outstanding. The presentations were the Inter-professional Day CLARION Competition; The Junior Doctors of Health Program and the Student Government Report.

Recommendation of Administration: That the report be received as information.

Recommendation of Committee: That the report be received as information.

Board Action: Report received as information.

Item 11. Amendments to the Faculty Senate Constitution.

Statement: Mr. Berlinsky stated that the Committee recommended approval of the Amendments to the Faculty Senate Constitution and asked for approval.

Recommendation of Administration: That the Amendments be approved as presented.
Recommendation of Committee: That the Amendments be approved.

Board Action: A motion was made the Amendments to the Faculty Senate Constitution be approved. It was seconded, voted and unanimously approved.

**Item 12. Creation of Eminent Scholar Designation.**

Statement: Mr. Berlinsky asked Dr. Raymond to discuss the Eminent Scholar Designation. Dr. Raymond said the designation would be an internal equivalent to an externally funded endowed chair. With the designation, the University would pledge at least $50,000 per year of support for five years to the recipient faculty member. At the end of five years, the Eminent Scholar designation could be converted to an endowed chair should funds be available. Alternatively, the Eminent Scholar designation cold be renewed for another five years. Administration believes this could address some perceived inequities at the University.

Recommendation of Administration: That the creation of the Eminent Scholar Designation be approved.

Recommendation of Committee: That the creation of the Eminent Scholar Designation be approved.

Board Action: A motion was made to approve the creation of the Eminent Scholar Designation. It was seconded, voted on and unanimously approved.

**Item 13. Other Committee Business.**

Mr. Berlinsky stated that since the Board had previously approved the QEP, there was no further Committee business.

**Item 14: Faculty Promotions.**

Statement: At the request of the Chair of the Department of Library Science and Informatics, administration presented for approval the following faculty promotion, effective January 1, 2007.

**Margaret P. Schachte, M.B.A.,** from Assistant Professor to Associate Professor, Department of Library Science and Informatics, effective January 1, 2007.

Recommendation of Administration: That this faculty promotion be approved.

Recommendation of Committee: That this faculty promotion be approved.

Board Action: A motion was made to approve the faculty promotion. The motion was seconded, voted on and unanimously carried.

**Item 15: Faculty Appointments.**

Statement: At the request of the Deans of the Colleges of Dental Medicine,
Medicine, the South Carolina College of Pharmacy, and the College of Nursing, administration presented for approval the following faculty appointments:

**College of Medicine and Dental Medicine**

Stephen M. Lanier, Ph.D., (joint appointment) as Professor with tenure in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics, effective December 1, 2006.

John S. Markowitz, Pharm.D., (joint appointment) as Associate Professor in the Department of Psychiatry and Behavioral Sciences, effective January 1, 2007.

Dr. Markowitz' primary appointment rests in the Department of Pharmaceutical Sciences, College of Pharmacy/SCCP.

**College of Medicine**

Marie-Florence Shadlen, M.D., Clinical Associate Professor, Department of Medicine, Division of General Internal Medicine, effective November 1, 2006.

**MUSC College of Pharmacy / South Carolina College of Pharmacy**

Philip D. Bell, Ph.D., (joint appointment) as Professor in the Department of Pharmaceutical Sciences, effective February 1, 2007.

Dr. Bell’s primary appointment rests in the Department of Medicine, College of Medicine.

Maurizio Del Poeta, M.D., (dual appointment) as Associate Professor in the Department of Medicine, Division of Infectious Disease, effective October 1, 2006.

Dr. Del Poeta’s primary appointment rests in the Department of Biochemistry and Molecular Biology, College of Medicine

**College of Nursing**

Janis K. Beckstrand, Ph.D., R.N., Adjunct Associate professor in the Department of Nursing, effective January 2, 2007.

Recommendation of Administration: That these faculty appointments be approved.

Recommendation of Committee: That these faculty appointments be approved.

Board Action: It was moved that the Board approve the faculty appointments. The motion was seconded, voted on and unanimously carried.

**Item 16: Changes in Faculty Status.**

Statement: At the request of the Dean of the College of Medicine, administration presented for approval the follow change in faculty status:

**College of Medicine**

Linda S. Austin, M.D. from Adjunct Professor to Clinical Professor, in the
Department of Psychiatry and Behavioral Sciences, effective January 1, 2007.

Recommendation of Administration: That this change in faculty status be approved.

Recommendation of Committee: That this change in faculty status be approved.

Board Action: It was moved that the Board approve the change in faculty status. The motion was seconded, voted on and unanimously carried.

Item 17. Post-Tenure Review.

Statement: Administration presented as information, the approved Post-Tenure Reviews for the following faculty appointments:

**College of Medicine**
Narendra L. Banik, Ph.D., Professor, Department of Neurosciences
Narayan R. Bhat, Ph.D., Professor, Department of Neurosciences
James A. Cook, Ph.D., Professor, Department of Neurosciences
Craig E. Crosson, Ph.D., Professor, Department of Ophthalmology
Rosalie K. Crouch, Ph.D., Professor, Department of Ophthalmology
Nancy Lynne S. Curry, M.D., Professor, Department of Radiology
David R. Garr, M.D., Professor, Department of Family Medicine
Sebastiano Gattoni-Celli, M.D., Professor, Department of Radiation Oncology
Ann-Charlotte E. Granholm-Bentley, Ph.D., D.D.S., Professor, Department of Neurosciences
Leonie Gordon, M.D., Professor, Department of Radiology
Barry L. Hainer, M.D., Professor, Department of Family Medicine
William J. Hueston, M.D., Professor, Department of Family Medicine
Joseph M. Jenrette, III, M.D., Professor, Department of Radiation Oncology.
Peter W. Kalivas, Ph.D., Professor, Department of Neurosciences
Henry F. Martin, Ph.D., Professor, Department of Neurosciences
Jacqueline F. McGinty, Ph.D., Professor, Department of Neurosciences
Steven M. Ornstein, M.D., Professor, Department of Family Medicine
Richard A. Saunders, M.D., Professor, Department of Ophthalmology
Stephen I. Schabel, M.D., Professor, Department of Radiology
Ronald E. See, Ph.D., Professor, Department of Neurosciences
William M. Simpson, Jr., M.D., Professor, Department of Family Medicine.
M. Edward Wilson, M.D., Professor, Department of Ophthalmology
W. Curtis Wise, Ph.D., Professor, Department of Neurosciences

**College of Nursing**
Gail W. Stuart, Ph.D., Professor, Department of Nursing

Recommendation of Administration: That these approved Post-Tenure Reviews be received as information.

Recommendation of Committee: That these approved Post-Tenure Reviews be received as information.
Board Action: Received as information.

Item 18: Eminent Scholar Designation to Robert G. Gourdie, Ph.D.

Statement: At the request of the Dean of the College of Medicine, administration presented as information, the designation of *Eminent Scholar in Developmental Cardiac Biology* to Robert G. Gourdie, Ph.D., Professor in the Department of Cell Biology and Anatomy, effective January 1, 2007.

Recommendation of Administration: That the Eminent Scholar in Developmental Cardiac Biology Designation to Robert G. Gourdie, Ph.D., be received as information.

Recommendation of Committee: That the Eminent Scholar in Developmental Cardiac Biology Designation to Robert G. Gourdie, Ph.D., be received as information.

Board Action: Received as information.

Item 19: Endowed Professor Designations.

Statement: At the request of the Dean of the College of Medicine, administration presented as information, the following named Endowed Chairs, effective February 9, 2007.

Kerry D. Solomon, M.D., as the Arthur and Holly Magill Endowed Chair in Ophthalmology.

Gene R. Howard, M.D., as the Stanley and Theodora Feldberg Endowed Chair in Ophthalmology.

Recommendation of Administration: That these named Endowed Chairs be received as information.

Recommendation of Committee: That these named Endowed Chairs be received as information.

Board Action: Received as information.

FINANCE AND ADMINISTRATION COMMITTEE. CHAIRMAN: MR. CHARLES W. SCHULZE. (Detailed committee minutes are attached to these minutes).

OLD BUSINESS: None.

NEW BUSINESS:

Item 20. General Report by the Vice President for Finance and Administration.

Statement: Mr. Schulze reported that Ms. Montgomery stated that the FY 07-08 budget packages will be distributed throughout the University this week. The
Finance Committee will meet in June for the purpose of approving the budget. The meeting will be held in Columbia and the date will be announced soon.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information


Statement: Mr. Schulze stated Ms. Susan Haskill presented the financial status report of the University and said current funds are tracking ahead of last year and the trend is expected to continue throughout the year.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.


Statement: Mr. Schulze said Mr. Bruce Quinlan reported UMA revenues year-to-date are $91 million as compared to $78 million last year.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.


Statement: Mr. Schulze said Ms. Janet Scarborough reported that the FRD has shown an improvement of about $77,000 in net assets since last November.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: Received as information.

Item 24. Other Committee Business.

None.

UNIVERSITY PHYSICAL FACILITIES COMMITTEE. CHAIRMAN: MR. WILLIAM H. BINGHAM, SR. (Detailed committee minutes are attached to these minutes).
OLD BUSINESS: None.

NEW BUSINESS:

Item 25. **Facilities Procurements/Contracts.**

Statement: Mr. Bingham said Mr. Malmrose attended an engineering awards banquet last evening in Columbia. The event was sponsored by the American Council for Engineering Companies of South Carolina. Guy White Associates was recognized for their work with the University’s high voltage sub-station and electric line replacement project. This was recognized as one of the top six engineering excellence accomplishments in South Carolina.

Mr. Bingham asked for approval for the following procurements/contracts:

- College of Nursing Clinical Teaching Lab Construction Project Scope Change: Total estimated budget: $2,500,000.
- Hazardous Weather Upgrades - Phase I fund source change/budget increase: Total estimated budget $856,000.
- Lease renewal for 75,100 square feet of warehouse space located at 4295 Arco Lane to provide space for University Record Center, Library Archives, Property Control, University Press and Materials Management: Total Cost of five-year lease: $684,000.
- Lease renewal of 2,614 square feet of clinical space located at 57 Bee Street to provide space for MUSC Employee Health Services. Total cost of five year lease: $171,720 with extended option of five years with terms to be negotiated.
- Lease renewal of 7,962 square feet of office space located at 20 Ehrhardt Street for Pharmacy Billing, Department of Radiology, Department of Neurology, HCC, Office of EEOC and Family Medicine. Total cost of five year lease: $261,540 with extended option of five years with terms to be negotiated.
- Lease renewal of 2,242 square feet of office space located at 28 Ehrhardt Street to provide space for the Office of Planning and Special Projects. Total cost of five year lease: $75,180 with extended option of five years with terms to be negotiated.
- Lease renewal of 3,327 square feet of office space located at 45 Bee Street to provide space for Internal Audit. Total cost of five year lease: $98,880 with extended option of five years with terms to be negotiated.

**Recommendation of Administration:** That these procurements/contracts be approved.

**Recommendation of Committee:** That these procurements/contracts be approved.

**Board Action:** It was moved that these procurements/contracts be approved. The motion was seconded, voted on and unanimously carried.
Item 26. Update on Projects.

Statement: Mr. Bingham stated that Mr. John Malmrose had provided an update on University projects to the committee.

Recommendation of Administration: That this be received as information.

Recommendation of Committee: That this report be received as information.

Board Action: The report was received as information.

Item 27. Other Committee Business. None.

Item 28. Facilities Contracts Awarded.

MEDICAL UNIVERSITY OF SOUTH CAROLINA AUDIT COMMITTEE. CHAIRMAN: THOMAS L. STEPHENSON, ESQ.

OLD BUSINESS: None

NEW BUSINESS:


Statement: Mr. Stephenson stated the Committee had received a report regarding the hiring of the External Auditor. The External Auditor Selection Committee recommended hiring KPMG for the next four-year cycle and asked for approval.

Recommendation of Administration: That the recommendation to hire KPMG to provide external audit services for FY 2007-2011 be approved.

Recommendation of Committee: That the recommendation to hire KPMG to provide external audit services for FY 2007-2011 be approved.

Board Action: It was moved, seconded and unanimously voted that the External Audit Services for FY 2007-2011 be provided by KPMG.

OTHER BUSINESS FOR THE BOARD OF TRUSTEES:

Item 30. Approval of Consent Agenda.

Statement: Approval of the University Consent Agenda was requested.

Recommendation of Administration: That the consent agenda be approved.

Board Action: It was moved, seconded and unanimously voted that the consent agenda be approved.
Item 31. New Business for the Board of Trustees.

Statement: Dr. Thomas stated that the regularly scheduled October 9-10, 2008 Board meeting date was in conflict with a religious holiday and made a motion that the date be changed to October 2-3, 2008.

Board Action: The motion to change the date of the October 2008 Board meeting from October 9-10 to October 2-3 was seconded, voted and unanimously approved.

Dr. Fishburne praised St. Luke’s Chapel as a great asset of the University. Mrs. Fishburne has said that the acoustics of the Chapel are outstanding. Dr. Greenberg said Mrs. Fishburne will have an organ recital on Tuesday at the Chapel and encouraged everyone who was in town to attend.

Dr. Greenberg thanked Mr. and Mrs. Hewitt for hosting the Trustees’ wives at their home on Thursday.

Item 32. Report from the Chairman.

No report.

There being no further business, the meeting of the University Board of Trustees was adjourned.

Respectfully submitted,

[Signature]
Hugh B. Faulkner III
Secretary

/wcj
Attachments
Since the December 8th meeting of the Board of Trustees, Dr. Greenberg’s activities have been concentrated in the following areas:

1. **Meetings with public officials:**
   a. Congressman Buyer – 12/13
   b. Governor Sanford – 12/13
   c. Mayor Riley – 1/16, 1/19, 2/5
   d. Governor Tommy Thompson – 1/18
   e. Presentation to House Ways & Means Committee, Education Subcommittee – 1/23
   f. Treasurer’s Staff – 1/31
   g. Treasurer Ravenel – 1/31

2. **Media Interviews/Invited Public Presentations:**
   a. Videotaping, WIS re CoEE – 2/1
   b. Welcome to Ernest Just Symposium – 2/2

3. **Presentations to/Meetings with MUSC constituencies:**
   a. CTSA meeting – 12/13
   b. Vice Presidents – 12/13, 1/3, 1/24
   c. Advanced Point of Care Clinical Steering Committee – 12/13
   d. Holiday Luncheon honoring retirees – 12/14
   e. Farewell reception for Dr. David Ward – 12/14
   f. Presentation to MUSC Trustee Leadership Academy – 1/19
   g. MUSC Night at the Ballet – 1/26
   h. President’s Council – 1/31
   i. Presentation to MUSC Women Scholars – 2/1
   j. New Faculty Welcome – 2/5

4. **Meetings with outside constituencies:**
   a. Ayers Saint Gross re hospital – 1/3, 1/31
   b. Martin Luther King Day Breakfast – 1/16
   c. Board of Scientific Counselors, National Council on Health Statistics – 1/16
   d. SCRA Board Meeting, Clemson – 1/17
5. **Meetings with members of local and non-local medical community:**
   a. Health Sciences South Carolina Board – 12/15, 1/25
   b. SCARN (Aging Research) – 1/19
   c. Mr. John Barilich, new director, VAMC – 2/7

6. **Meetings with donors:**
   a. Development lunches – 12/11, 12/15, 1/19
   b. Development dinners – 1/3, 1/6, 1/22, 1/24, 1/26
   c. Development phone calls – 12/11, 1/24, 1/30, 2/5
   d. Development visits – 1/16, 1/19, 1/22, 1/24
   e. Development visit, Charlotte – 1/23
   f. Governor’s Mansion HCC Awareness Reception – 12/13

7. **Collaborative discussions:**
   a. Johnson Controls – 12/12
   b. Dr. Rahn, Medical College of Georgia – 12/13
   c. Presidents Sorenson and Barker – 12/19
   d. Project Cardio – 1/2
   e. Siemens – 1/29
   f. Hillenbrand/Hill-Rom – 1/31
   g. Hospital Launch – 2/2
   h. Dr. Harris Pastides – 2/2
MUSC is focusing on aggressive programs of research, development and commercialization with the goal of establishing South Carolina as a biotechnology center.

Research is vital, development is critical, but transfer is the Holy Grail of R&D. The Medical University of South Carolina (MUSC) is focusing on all three with a spotlight on "translational research" that turns theoretical research into tangible products. Whether it’s saving someone from permanent scarring, reducing the ravages of diabetes, finding new treatments for chronic pain or developing new anticancer drugs, MUSC is focused on research that will generate products to save and improve the lives of millions.

With funding agencies such as the National Institutes of Health placing heavy emphasis on rapid clinical developments, MUSC is moving aggressively forward with a mandate to take drug discoveries from the bench to the bedside.

That mandate is inspiring resourceful partnerships between the university and industry as well as spin-out companies that drive local economic development and job creation.

“The political leadership in South Carolina is working aggressively to build the knowledge economy in the state,” said MUSC President Dr. Ray Greenberg. “We at MUSC have heard that message and committed ourselves to taking basic research from the lab and applying it to benefit patients. That will also benefit the community by creating high-tech, high-paying jobs.”

A collaborative mindset

The MUSC Foundation for Research Development (FRD) is backing the university’s translational role. Set up as a not-for-profit entity, the Foundation seeks to initiate and sustain cooperation, collaboration and the transfer of ideas between MUSC and industry.

The FRD has three goals: commercializing MUSC-created intellectual property, facilitating research collaborations between MUSC and industry and furthering MUSC’s public service mission by fostering health care-related economic development. Practically speaking, the foundation bridges the gap between the public and private sector by offering MUSC’s ideas, technology and expertise to industry and, ultimately, for public use.

For more information about commercializing the breakthrough technologies developed at MUSC, contact the MUSC Foundation for Research Development at 843.876.1900. Or, visit www.musc.edu/frd where you can browse technology available for licensing by type.
"The academic sector and the private sector each have something to contribute," said Dr. Mark Kindy, assistant provost for technology transfer and corporate relations at MUSC. "We have the faculty and scientists at MUSC who make new discoveries and test whether products will be effective in a human therapeutic situation. Meanwhile, industry brings the business and management expertise to the commercial development and operations arena."

Advancing health care-related economic development for South Carolina and the nation is a vital part of MUSC's work, says FRD Executive Director Chip Hood. Hood, a patent attorney, calls it "knowledge-based economic development" and is convinced that if MUSC only conducts research without tapping into the economic rewards of commercialization, then South Carolina will be shortchanged.

"Increasingly, leading-edge research at MUSC is creating opportunities for South Carolina-based companies," Hood said. "Beyond the direct economic impact of the research itself, there is the potential to use the resulting ideas and knowledge to create new products and services from which the university, the community and the public will benefit."

Licensing breakthrough technologies
When MUSC researchers discover a breakthrough that could be valuable in the commercial marketplace, the FRD works to secure patents and negotiate and manage licensing and research agreements. The FRD then evaluates the business potential of the research development and prepares to market it to the private sector.

"The FRD identifies the best possible place to transfer technology so it can be developed into a commercially viable product," Hood said. "That may be a large pharmaceutical company or a small startup company. More and more we are seeing startups born out of MUSC technology staying in South Carolina to set up shop. That is evidence of how far we've come and how the state's biotechnology infrastructure is growing."

Spinning out new companies
When there is a clear business opportunity to commercialize an innovation locally and with MUSC researchers, the FRD helps those researchers form spin-out companies. "We've placed an emphasis on technology transfer at MUSC. It is now part of our core mission," Greenberg says. "We have always been devoted to education, research and patient care. Now we are learning how to help grow the economy, and through these efforts broaden the number of people that we can benefit."

FRD at a glance:
Historically since FRD inception,
• More than 400 new discoveries from MUSC
• 43 issued United States Patents
• 23 exclusive license agreements
• 13 startup companies
• More than $4.7M in license income generated
• Numerous sponsored research agreements with industry
Argolyn Bioscience: Peptides to the Rescue

As a home-grown startup company born at MUSC, Argolyn Bioscience has raised $3.5 million to fund R&D on discoveries that will address major unmet medical needs such as psychoses and chronic pain.

Argolyn originally was founded based on technology developed by Dr. Thomas A. Dix, associate professor of pharmaceutical sciences in the South Carolina College of Pharmacy and now Argolyn’s chief scientific officer. The technology consists of a series of chemical modification techniques that optimize peptides—fragments of proteins that are key components of cell structure and function. Genetic diseases are linked to protein malfunction, and adding a suitable peptide to mimic a functioning protein can reduce or eliminate symptoms.

Argolyn scientists start with a known peptide and then modify it so that it can be formulated into a drug. The Argolyn technology platform stabilizes peptides so that they stay in the body longer and can be delivered more efficiently to the target organ. Without these modifications, peptides would break down rapidly in the body before they could do their work.

The technology already has been used to derive promising new drug candidates for schizophrenia and pain. Argolyn’s lead anti-schizophrenia product and its second product for pain will be first-in-class therapeutics if they are approved by the FDA. Since the general approach can be used for a wide range of illnesses, many different applications may be developed over time.

**Argolyn’s Economic Impact**
- $3.5 million raised, including more than $1.8 million in NIH awards
- More than 90 percent investment from outside the state
- $800,000 returned to MUSC in research support, license fees and patent costs
- Housed in a HUBzone facility renovated by Argolyn

A homegrown success story

Argolyn’s story begins in 1995 in a lab at MUSC where Dix discovered and developed the technology. A patent application was filed in 1996, but the project did not catch the attention of Pearce Gilbert, then at the MUSC Foundation for Research Development (FRD), until 2000 when he and Dix began sketching out a business plan based on the technology. With the award of a National Institutes of Health (NIH) small business grant in September 2002, Argolyn Bioscience was born. With just six months of support, Argolyn Bioscience set up shop in Mount Pleasant and hired Gilbert to run the company and manage the grant.

“Pearce Gilbert was the logical choice to lead the company. He was the one who first suggested that my research program could be the basis for a new company. He was instrumental in Argolyn’s conceptualization,” Dix said. After four years, the company has continued to expand by raising more money, growing its leadership team and advancing its drug development.
programs. MUSC’s Foundation for Research Development (FRD) has played a key role in the company’s development. The FRD incubated Argolyn during its conceptual stage and eventually licensed the technology and patents to the company. Argolyn already has returned approximately $800,000 to MUSC and the FRD in the form of license fees, patent expense reimbursements, royalties on sales and research support. The licensed inventions give Argolyn Bioscience the exclusive rights to drug candidates already in development and the technology platform from which these three products were developed.

“Not only did it give us the means for developing our own products, but also an incredible technology platform that can be sublicensed to other drug development companies in very specific fields of use,” Gilbert said.

Argolyn is credited with several important firsts in the South Carolina biotech startup arena. In the fall of 2004, Argolyn was the first company from South Carolina to present at the Southeastern BIO Investor Forum, recognized as the Southeast’s premier life sciences venture capital conference. With presenting companies selected by a panel of top venture capitalists from around the country, the Investor Forum annually showcases more than 30 regional life sciences companies in front of investors representing billions of dollars in investment potential.

In 2005, Argolyn was invited to present again when the conference was held in its hometown of Charleston. ImmEDIATELY FOLLOWING THAT PRESENTATION, GILBERT WAS APPROACHED BY A REPRESENTATIVE FROM THE SOUTH CAROLINA RESEARCH AUTHORITY’S (SCRA) SC LAUNCH! PROGRAM. SC LAUNCH! SUPPORTS QUALIFIED ENTREPRENEURS AND RESEARCHERS WITH KEY TOOLS FOR SUCCESS, PROVIDING HIGH-POTENTIAL SOUTH CAROLINA-BASED COMPANIES WITH A MIX OF UP-FRONT COUNSELING, FACILITIES, SEED FINANCING AND ONGOING MENTORING. IN EARLY 2006, ARGOLYN BECAME THE FIRST COMPANY TO RECEIVE FINANCIAL SUPPORT FROM SC LAUNCH! THE SC LAUNCH! FUNDS WERE MATCHED BY OUT-OF-STATE INVESTORS FOR EVEN LARGER FINANCING.

“It is quite satisfying to look back on the progress we’ve made over the last four years. A lot of people were betting Argolyn wouldn’t last six months,” Gilbert said. “However, we’ve just continued to build the company and move our product development programs forward.”

---

**MUSC is building two new facilities to expand research and tech transfer**

MUSC Drug-Discovery Center:
- Will hold research devoted to drug development, especially for cancer drugs.
- Will give researchers better access to advanced technology needed to enhance drug discovery and distribution.

MUSC Bioengineering Building:
- Will house the development of new treatments for cancer, cardiovascular and neurological disorders.
- Will be the focal point of a statewide collaboration integrating faculty, students and staff from MUSC, USC and Clemson University.

Facilities are expected to help attract entrepreneurial faculty who will spur economic development.

Buildings are being funded in part through the S.C. Research University Infrastructure Bond Act.
Human tissue is programmed to mend itself after an injury, but it often does an imperfect job. The body rarely rebuilds a damaged area exactly as it was before, which often results in a scar. At the Medical University of South Carolina, two researchers have created a healing treatment they hope will reduce or even eliminate the formation of scar tissue.

The treatment’s viability also would secure the future of FirstString Research, a biotechnology company that was formed to produce, market and distribute the healing technology. The company could create high-paying jobs at its North Charleston headquarters and bring in millions of dollars in licensing revenue and capital investment to MUSC and the Charleston region.

More than skin deep

Scarring can create problems in almost any part of the body after injury or surgery, from a scratched cornea to an injured spinal cord.

The issue, according to Dr. Rob Gourdie, a professor of cell biology at MUSC, is how to shift the balance of the healing process from scar formation to the growth of normal, functioning tissue. “If there’s a lot of scar tissue (at a wound site), there’s no space for the regeneration of healthy tissue,” Gourdie explained.

For the past decade, Gourdie has been studying how cells communicate with one another to perform certain tasks, including wound repair. Based on this research, he bio-engineered a molecule that appears to modify the communication between cells. Gourdie and post-doctoral fellow Dr. Gautam Ghatnekar since have been investigating the use of this molecule in speeding the healing process and in reducing or eliminating the occurrence of scarring.

Healing is their business

Officials at MUSC’s Foundation for Research Development (FRD) recognized the potential of Gourdie and Ghatnekar’s discovery when the pair approached the organization about
commercializing their product. MUSC owns the intellectual capital produced by its researchers, and FRD handles patent applications and licensing for commercially viable discoveries coming out of the university.

With the help of FRD, the two researchers founded FirstString Research in June 2005 as a spin-off biotechnology company from MUSC. Ghatnekar became president of the company and Gourdie its chief scientific officer. FirstString has signed a licensing agreement with MUSC, and U.S. and international patents are being processed.

While FRD officially represents the university in licensing negotiations, the organization wants to help businesses that are attempting to commercialize the research as much as possible. According to Yashmin Karten, a licensing manager with FRD, the staff helps connect start-ups with the resources that exist to help new companies be successful.

“Groups like SCBiO (the South Carolina Biotechnology Incubation Program), SC Launch!—we have direct relationships with these entities to help companies find the assistance they need,” Karten said.

In fact, FirstString was one of the first SC Launch! companies funded by the South Carolina Research Authority (SCRA). FirstString received $15,000 from SCRA for early product testing, and the company is under consideration for an additional $200,000 grant. SC Launch! is a collaborative effort among SCRA and South Carolina’s three research universities. The program provides counseling, seed money and ongoing mentoring to technology start-ups.

FirstString also was recently awarded a $150,000 small business technology transfer grant from the National Institutes of Health, which is paying for further product testing necessary for FDA approval. The grant award has affirmed that Gourdie and Ghatnekar’s discovery has the potential to become the basis for a long-term commercial enterprise.

Just scratching the surface

“We’re quite pleased with the results,” Gourdie said of the early rounds of product testing that are being completed in vitro and on animal models. Last summer, FirstString had its initial meeting with the FDA, which helped outline a path to human trials once current testing is completed. FirstString officials believe Phase I testing in humans can begin by August 2007.

While FirstString’s founders believe the initial market for their product will be patients undergoing plastic surgery who wish to minimize scarring for cosmetic reasons, they are also excited about the potential for the peptide to help everyone from burn victims to injured combat troops. The treatment even may have a future role in organ regeneration. “You could see our peptide and stem cells working in partnership with one another,” Gourdie said. “I call what we’re doing regenerative healing.”

MUSC attracts world-class researchers

MUSC has recruited seven nationally renowned scientists since May 2004 as part of a state program created to bring more cutting-edge research to South Carolina.

The Research Centers of Economic Excellence program calls for the state’s three research universities to raise private money to fund professorships in fields where there is high potential to commercialize research and create well-paying jobs. The universities then can receive state funds to match (dollar for dollar) the private funds raised. This matching money doubles the financial resources available to fund each professor’s innovative research and increases the potential of the research to generate wealth and create better job opportunities for South Carolina’s citizens.

Researchers recruited to MUSC under the Research Centers of Economic Excellence program:

Dr. Gary Aston-Jones, neuroscience
Dr. John J. Lemasters, advanced cellular technologies
Dr. Miguel A. Pappolla, neuroscience
Dr. John J. Schaefer, clinical effectiveness and patient safety
Dr. Charles D. Smith, pharmaceuticals
Dr. Richard W. Swaja, regenerative medicine
Dr. Kenneth D. Tew, drug discovery in cancer
Apogee Biotechnology:
Inhibitions That Can Save Your Life

In addition to launching startup companies from its research innovations, the Medical University of South Carolina (MUSC) also is using its resources to attract outstanding scientists who, in turn, help to attract new life sciences companies to South Carolina.

In 2005, Dr. Charles Smith was recruited to fill an endowed chair at MUSC under South Carolina's Research Centers for Economic Excellence Program. He also directs MUSC's new Drug Discovery Program, which has a goal of identifying and developing compounds that have potential therapeutic value.

The efforts at MUSC are right up Smith's alley. He brings five years of experience as director of a similar facility he established at Penn State University. It was during his tenure there that he launched Apogee Biotechnology Corp., a company that has set out to discover and develop new pharmaceutical agents for the treatment of chronic and life-threatening diseases. Hershey, Pa.-based Apogee is bringing some of its operations to Charleston, so that it can collaborate with MUSC. "I want to see Apogee collaborate with MUSC to explore chemistry and biochemistry research here, like some MUSC spin-out companies have done in the past," Smith explained.

Health. Smith, who holds seven patents, is focused on the development of anticancer drugs, specifically for breast cancer. He also is interested in the development of compounds for HIV, acute renal failure, diabetic retinopathy and arthritis.

Apogee's technologies involve Sphingosine kinase (SK), an innovative molecular target for therapy. SK plays a critical role in regulating cell proliferation and activation. SK inhibitors are expected to find a place in treating a variety of inflammatory and vascular diseases and Apogee is at the forefront of this therapeutic revolution.

So many benefits, so little time
Founded in 2001, Apogee receives funding from eight Small Business Innovation Research grants totaling $2.7 million from the National Institutes of Health. Smith is looking forward to the University of South Carolina in many ways:

Build it and they will come
MUSC officials are excited about the benefits that Apogee can bring to treating so many serious health conditions and Smith is looking forward to advancing drug discovery through his partnership with MUSC.

"The biotech infrastructure is still developing in South Carolina, as it is in many places, but I think the most important thing in helping to advance biotechnology is a strong research university that attracts and develops good people and good ideas. MUSC fits that bill," Smith said. "There is real interplay between Apogee and MUSC. It's a two-way street, and value comes back to South Carolina in many ways."
"I got involved in diabetes research because of my personal passion," said Robert A. "Bob" Faith, whose daughter, Stuart, developed type 1 diabetes at age 3.

After Faith’s wife called him with the bad news as he was flying to Seattle for business, he couldn’t get a return flight for 12 hours. He spent that time on the Internet researching diabetes and what Stuart’s diagnosis would mean for his family.

"I decided that I wanted to do something about it," Faith said.

He took Stuart to the Medical University of South Carolina’s Children’s Hospital because of its strong reputation in the region, and Dr. Lyndon Key, MUSC researcher and physician, became her doctor. Out of that relationship (and based on cutting-edge research that Key and Dr. Inderjit Singh already were performing at MUSC), Immunomod was born.

Today, Immunomod, LLC, a spin-out company of MUSC, is a privately held biotechnology company based in Charleston. Faith, Immunomod’s chairman, says the company’s mission is to develop novel therapeutics to alleviate human suffering caused by diabetes and related auto-immune disorders.

A hospital, a lab, a company

Key, who is the chair of the pediatrics department at MUSC and physician-in-chief at MUSC’s Children’s Hospital, was the company’s co-founder along with Singh, who is the Distinguished University Professor of Pediatrics and scientific director of the Children’s Research Institute (CRI) at MUSC. The CRI is the first research facility in the Southeast dedicated to research on the illnesses of children. Located near the nationally recognized MUSC Children’s Hospital, the CRI helps bring the latest discoveries into clinical use, and Immunomod is helping to speed these discoveries into commercial application.

Immunomod is working on drug development prospects for both type 1 and type 2 diabetes; however, the company’s initial focus is on type 1, or juvenile diabetes. Immunomod’s core scientific approach involves blocking the root of the disease — the body’s attack on insulin-producing (beta) cells. According to Faith, the company’s goal is to create the first sustainable and safe treatment for the prevention and cure of early-stage type 1 diabetes.

Following promising Phase I trials, Immunomod soon will start an FDA Phase II trial with approximately 60 juvenile patients.

“We are very excited to start seeing our ideas and research beginning to have an impact on children’s lives,” Faith said. Immunomod continues to actively grow its patent and drug portfolios through research collaboration with MUSC and targeted in-licensing of complementary products and treatments. “If we’re successful, then the university becomes more successful because of it,” Faith said.

Immunomod recently received its first round of private funding and is using the capital to fund new research, continue to strengthen its intellectual property and build up the company’s long-term management team. Faith sums it up: “This is fascinating science with world-class people, and it’s all happening right here in South Carolina.”
Executive Summary of SACS Quality Enhancement Plan (QEP)
Creating Collaborative Care (C³)
MUSC Board of Trustees – February 9, 2007

The focus of the Quality Enhancement Plan (QEP) for the Medical University of South Carolina (MUSC) is interprofessional education, and has been entitled Creating Collaborative Care (C³). This initiative responds to the fact that today's health care system is highly complex and involves interaction of many different health care professionals in providing optimal patient care and advancing biomedical research. C³ will establish the framework for redesigning MUSC's formal and informal educational programs whereby future graduates not only continue to excel in the academic challenges of their own chosen profession, but additionally excel in today's complex interprofessional health care system.

The educational offerings of MUSC have been distinguished by the rigor and intensity of each college: dentistry, graduate studies, allied health professions, medicine, nursing and pharmacy. While their excellence is well established and recognized for preparing individual providers of clinical care and biomedical research, there is a growing concern nationally that the continuum of health care could be greatly improved. As suggested by an increasing number of articles, most notably in a series of reports by the Institute of Medicine (IOM), an improved health care system should be safe, effective, patient centered, timely and efficient. One of its four recommendations deals with preparing the health care workforce with emphasis on interdisciplinary teamwork as a necessary approach to increase patient safety and improve health care delivery.

MUSC was chartered in 1824 as the first medical school in the southern United States. The five sister colleges were established on various dates between 1881 and 1966. As with most academic medical centers, the additional colleges were added to the enterprise because of the value their professions contributed to the clinical practice of medicine. Each subsequent educational program was established with a great deal of autonomy, owing primarily to its unique specialty and accreditation requirements. Because of increased dependencies and complexities among the specialties, there is increased recognition that the educational and training aspects of each specialty should be modified to better prepare students for careers that will rely increasingly on teamwork and teamwork skills. C³ is MUSC's approach to building an academic and institutional culture that not only appreciates and values the need for interprofessional training, but that provides opportunities for effective integration of this knowledge and skill into health care delivery or research prior to graduation.

From an educational perspective, C³ offers a continuum of knowledge and teambuilding experiences, from acquisition, to application, to demonstration. It represents a dynamic process of student engagement in increasingly more sophisticated and expansive opportunities promoting and advancing interprofessional education while receiving their formal education. Each step of this continuum is motivated by four inter-dependent goals:

**Goal 1:** Students will acquire a set of defined teamwork competencies -- knowledge, values, attitudes, personal and interprofessional skills, principles, beliefs and standards.

**Goal 2:** Students will acquire knowledge, including the values and beliefs, of health professions different from their own discipline that will enable them to define interprofessional health care delivery or research.
Goal 3: Students will apply their teamwork competencies in a collaborative interprofessional health care delivery or research learning setting.

Goal 4: Students will demonstrate their teamwork competencies in a collaborative interprofessional health care delivery or translational research context.

These goals will be achieved through a carefully structured organization that focuses on four primary domains: formal curriculum; informal extracurricular activities; the Teaching Scholars Academy; Clinical Effectiveness and Patient Safety. Each of these domains will have a Team Leader who will report to the C3 Director having overall responsibility for the initiative within the Office of the Associate Provost for Education and Student Life. A proposed C3 Council, chaired by a senior academic officer, will be established to assist the C3 Director in reviewing progress, resolving major barriers, and addressing major changes/improvements. In addition, an Assessment Team will be composed of institutional researchers to provide objective analysis to issues requested by the Associate Provost, the C3 Council and/or the C3 Director. One of their primary tasks will be to assess the progress of C3 regarding QEP standards.

MUSC faculty, staff, and students understand C3 as an essential pathway to improving education and tie the provision of health care at all levels with all professions working together. If successful, it may also serve as a model for other academic health centers.
Medical University of South Carolina

RESEARCH AND INSTITUTIONAL ADVANCEMENT COMMITTEE

MINUTES

February 8, 2007

Committee Members Present: Mr. William H. Bingham, Sr., Dr. Cotesworth P. Fishburne, Jr. (Chair), Mr. William B. Hewitt, Dr. Donald R. Johnson, II, Dr. Thomas C. Rowland, Mr. Thomas L. Stephenson, The Honorable Robin Tallon, Dr. James E. Wiseman

Members Not in Attendance: Dr. Paula E. Orr,

Other Trustees Present: Dr. Stanley C. Baker, Jr., Dr. Charles B. Thomas, Jr.

Other Participants: Mr. Thomas P. Anderson, Ms. Susan H. Barnhart, Mr. Jim Fisher, Dr. John R. Feussner, Dr. Ray Greenberg, Mr. William C. Hood, Dr. Stephen M. Lanier, Ms. Leigh W. Manzi, Dr. John R. Raymond, Ms. Margaret P. Schachte, Ms. Elizabeth P. Waters

Regular Agenda

Call to Order and Approval of Minutes
Dr. Fishburne called the meeting to order at 1:00 PM in the Colcock Hall Board Room. The minutes of the previous meeting were approved as distributed.

Item 6. General Report of the Associate Provost for Research
Dr. Lanier started by acknowledging Dr. Raymond’s contributions and complimenting him on his high standards of excellence in filling the role of Associate Provost for Research since 2001. Dr. Lanier distributed the January 2007 Monthly Summary of Grants and Contract Activity to supplement the December monthly report included under Tab 4 of the meeting booklet. He then reported briefly on university research activities, Year-to-date total dollars of grants and contracts awarded in FY2007 are slightly ahead of the same period for the previous two fiscal years. In January 2007 MUSC booked 71 awards valued at $7.7 million. Major initiatives under development include the NIH Clinical and Translational Science Award proposal, involving ongoing discussions with the University of South Carolina and the Medical College of Georgia as potential partners, and a National Science Foundation Research Infrastructure Initiative proposal, which emphasizes statewide collaborative activities with Clemson and USC with a possible focus on computational sciences. Since arrival in early December, Dr. Lanier has concentrated his attention on MUSC research support services. Initiating an update of the research strategic plan, resonating with the university strategic plan, is a near-term goal.

Recommendation of Administration. That the report be received as information.

Recommendation of Committee. That the report be received as information.

Board Action. N/A

Item 7. General Report of the Vice President for Development
Mr. Fisher presented the general report on institutional advancement activities. Development and fundraising commitments through December 31, 2006, total more than
$30 million. Mr. Fisher highlighted several of the numerous new gifts and bequests that are listed in the meeting booklet as well as the full Board agenda. These include major gifts to the College of Medicine’s Department of Surgery, College of Nursing, College of Dental Medicine, College of Graduate Studies, Hollings Cancer Center, Center of Excellence in Clinical Effectiveness and Patient Safety, the Children’s Hospital, and the Heart and Vascular Center. The MUSC component of the Trident United Way Campaign surpassed its $200,000 goal, thanks largely to the campus leaders: Drs. Mary Mauldin, Lynne S. Nemeth and Joseph (Buddy) Jenrette. The Department of Medicine in the College of Medicine, chaired by Dr. Feussner, recently created a new Director of Development position and recruited Ms. Jane McCullough, who has provided outstanding service as MUSC’s Director of Planned Giving. The University Development Office will recruit aggressively to fill the Planned Giving position, which is crucial to the Capital Campaign. The quiet phase of the Capital Campaign continues to progress well, with more than $88 million raised towards the $300 million goal. Since the December board meeting, the focus has been on establishing the Campaign Cabinet, confirming the priority initiatives and communications and marketing plans, projecting personnel additions, and establishing the campaign budget. A current goal is to host the inaugural meeting of the Campaign Cabinet by March 31. Specifics of the Campaign plan will be shared at the next Board meeting, after Cabinet approval.

Recommendation of Administration. That this report be received as information.

Recommendation of Committee. That this report be received as information.

Board Action. N/A

Item 8. General Report of the Chief Executive Officer of the MUSC Foundation
Mr. Tom Anderson reported on MUSC Foundation activities. The Foundation had an investment performance return of 12.2% for the 2006 calendar year. This level of performance is sufficient to cover inflation, run the Foundation, meet the endowment payout rate of 5.0% for beneficiaries, and enhance assets to support additional payouts in the future. As of December 31, 2006, total assets of the MUSC Foundation were more than $255 million.

Recommendation of Administration. That this report be received as information.

Recommendation of Committee. That this report be received as information.

Board Action. N/A

Item 9. Other Committee Business

General Report on Foundation for Research Development
Mr. Hood presented a general report on the MUSC Foundation for Research Development. He mentioned 3 current license negotiations, all involving additional funds for research agreements. The largest of these negotiations involves $930,000 of associated research support. The potential partner is a very large pharmaceutical company who was attracted to MUSC in part because of the research and development potential of the Health Sciences South Carolina (HSSC) statewide collaborative initiative.
Dr. Greenberg also recognized Mr. Hood’s critical involvement in supporting efforts of the Chamber of Commerce and others to recruit a major biotech company to the state.

Recommendation of Administration. That this report be received as information.

Recommendation of Committee. That this report be received as information.

Board Action. N/A

Faculty Presentations
Dr. Lanier introduced James Norris, Ph.D., Professor and Chairman of the Division of Microbiology & Immunology, and Michael Nishimura, Ph.D., Associate Professor of Surgery and Microbiology & Immunology. Dr. Norris gave an excellent overview on The Center for Cell Gene and Vaccine Therapy. The Center was created almost two years ago, largely through the collaborative efforts of Drs. Cole, Norris, and Kraft. It is in its second year of center seed funding provided competitively through the Provost’s Office. The Center’s overarching goals are to bring basic preclinical laboratory studies to preclinical Phase I research in humans and create new opportunities at MUSC to study novel gene therapies, stem cell therapies, and vaccine therapies related to cancer. Dr. Norris pointed out significant improvements in death rates caused by various other major diseases, whereas the cancer death rate has remained virtually unchanged since 1950. The Center was instrumental in helping to organize and administer a Cancer Gene Therapy meeting in Shenzhen, China, which proved to be the largest International Society of Cell and Gene Therapy conference to date, with more than 300 scientists attending. The continued development of the Center will assist in the competitiveness of the HCC P30 application, scheduled for submission in June 2008. The Center will also help MUSC meet the criteria for the NIH Clinical and Translational Science Award (CTSA) grant. The Center was a significant factor in the successful recruitment of Dr. Nishimura, who joined the MUSC faculty in the fall of 2006.

Dr. Nishimura came to MUSC from the University of Chicago, where he was Associate Professor of Surgery and Director of the Surgical Oncology Laboratories. A significant factor in his decision to join MUSC was the caliber of the research opportunities, the quality of the research facilities, and the level of institutional commitment to high-risk, high-impact research. His area of research focus is development of novel immune therapies for treatment of cancer. In the early days of the “War on Cancer,” the three main treatment modalities available were surgery, radiotherapy and chemotherapy. The fourth approach, immunotherapy, has been slow to develop, and is now taking off as a result of major advances in molecular and genetic knowledge in the past 20 years. Immunotherapy represents a promising avenue to treat cancers that are widespread and prevent their recurrence. Dr. Nishimura gave several examples of immunotherapies that use cytokine- and vaccine-based approaches. He then described a more recent development called T Cell Adoptive Transfer, which involves harvesting immune T cells from the patient, isolating and expanding them, and re-infusing them in the patient. Dr. Nishimura’s lab is exploring a gene/receptor-based approach to bypass the idiosyncrasies and inherent difficulties of T Cell Adoptive Transfer. This novel approach involves isolating the gene(s) from effective T cells that recognize the pathogen (or cancer cell) and engineering anyone’s cells to activate against the pathogen (or cancer). His lab team is currently working to develop clinical trials with two receptors at MUSC, with a plan to initiate the first Phase I trial in late summer of 2007, contingent on the
schedule to obtain FDA validation and commission the clean cell isolation facility. The availability of and institutional support for this facility was one of the primary reasons that Dr. Nishimura moved to MUSC.

**Recommendation of Administration.** That this report be received as information.

**Recommendation of Committee.** That this report be received as information.

**Board Action.** N/A

There being no further business, the meeting was adjourned at 1:55 PM.
EDUCATION, FACULTY AND STUDENT AFFAIRS COMMITTEE. CHAIRMAN: MR. MELVYN BERLINSKY

MINUTES
February 9, 2007

Members Present: Mr. Melvyn Berlinsky; Dr. Don Johnson; Dr. Stanley Baker; The Honorable Robin Tallon; Mr. William Bingham; Mr. Bo Faulkner; Dr. Conyers O’Bryan; Dr. Thomas Rowland; Mr. Charles Schulze; Mr. Thomas Stephenson; Dr. Charles Thomas.

Other Participants: Ms. Susan Barnhart; Dr. Amy Blue; Ms. Jo Ann Bolchoz; Ms. Scotty Buff; Dr. Frank Clark; Mr. Mark Daniels; Ms. Brie Dunn; Dr. Joe DiPiro; Mr. Aaron Embry; Dr. Jack Feussner; Dr. David Garr; Mr. Joe Good; Dr. Ray Greenberg; Dr. Perry Halushka; Mr. Robert Hendrix; Dr. Arnold Karig; Dr. Maralynne Mitcham; Dr. John Raymond; Dr. Jerry Reves; Dr. Jack Sanders; Ms. Manasi Sinha; Ms. Karen Spry; Dr. Gail Stuart; Dr. Becki Trickey; Dr. Valerie West.

REGULAR AGENDA

Item 10. General Report of the Vice President for Academic Affairs and Provost

Statement: A general report was given by Dr. John Raymond, as follows:

Quality Enhancement Plan for MUSC SACS Reaffirmation of Accreditation

Dr. Raymond introduced Dr. Amy Blue, who has assumed leadership of the Quality Enhancement Plan (QEP), an essential requirement for MUSC’s SACS Reaffirmation of Accreditation. Dr. Blue gave a succinct overview of the Plan to be submitted on March 8, 2007. On behalf of Administration, Dr. Blue requested approval of the plan.

Board Citation for Ms. Jo Ann T. Bolchoz

Dr. Valerie West, Associate Provost for Education and Student Life, presented a Board Citation to Ms. Jo Ann T. Bolchoz, Executive Director of the Harper Student Center, for her excellent service, long-time commitment and dedication to MUSC students, the university at-large, and the community.

Student Presentations

Interprofessional Day CLARION Competition

Dr. West introduced MUSC students, Brie Dunn, Aaron Embry, Manasi Sinha, Robert Hendry and Karen Spry, who gave an overview of the CLARION Competition a national initiative focused on interprofessional team collaboration and patient safety, and presented an abbreviated version of their winning CLARION case study. The winning team will enter CLARION’s national competition this April to be held in Minnesota. Dr. Maralynne D. Mitcham was recognized for her superb guidance as their mentor in the competition. The team was presented a plaque for their superb performance. Dr. Anthony Chipas was also recognized for his contributions to the CLARION program.

Junior Doctors of Health Program

Dr. West introduced Ms. Scotty Buff, founder and Director of the MUSC Junior Doctors of Health Program, and a College of Graduate Studies Student. The program has been focused on teaching Fraser Elementary students about the importance of nutrition and exercise for the past four years via an effort that originally began as part of the MUSC Presidential Scholars Program. The concept is to teach children in the community at a young age to integrate healthy living into their lifestyles.

Student Government Report

Mr. Michael Drake, SGA President, and Mr. Richard Webb, SGA Academic Vice President, and Ms. Brie Dunn, SGA Program Vice President, gave a brief overview of the
Student Government Association’s activities. Activities entailed improvement of student welfare (in particular, designated smoking areas; student on-campus parking needs; and efforts to create safe walking environments for students); and programs to enhance interprofessional interaction among students. The SGA is continuing to evaluate and amend the SGA constitution to improve the methods by which the Senate evaluates students concerns and campus issues and coordination of the MUSC Honor Council to ensure the integrity of students. They are working with university staff to improve accessibility and appropriate use of the Education Center and Library. Other efforts include increasing volunteer service participation, improving interprofessional communication, and improving student voter turnout for upcoming student elections.

College Highlights

Dr. Jerry Reves, Dean of the College of Medicine, gave a brief summary of initiatives that the College will be focusing on to include commitment of Excellence (Studer Professional Consultants), collaboration with USC and MCG on the CTSA application due for submission in October 2007, opening of the new hospital and planning for Phase II, activities involved with the newly formed Teaching Academy, efforts to improve interprofessional education, and MUSC’s SACS Reaffirmation of Accreditation.

Dr. Gail Stuart, Dean of the College of Nursing, reported that students achieved a 92% pass rate on the State Board exams, which exceeds the State and National average. She also distributed a brochure from the South Carolina Hospital Association titled, “Imagine South Carolina in a Homeland Nursing Crisis – One Voice/One Plan”, a program which is designed to address the nursing shortage in the State of South Carolina.

Dr. Perry Halushka, Dean of the College of Graduate Studies, gave a brief report on the College’s recruitment efforts for the Ph.D. and M.D./Ph.D. programs, and stating that all applicants are excellent this year with an average MCAT of 34.

Dr. Halushka briefly mentioned the success of the College’s Summer Undergraduate Program and the recent E. E. Just Symposium.

Dr. Joseph DiPiro, Executive Dean of the South Carolina College of Pharmacy briefly commented that the College’s applicant process is going well. Dr. Sarah Ball has accepted the position of Program Director of the Medicaid Academic Detailing Program. She will assume her duties on February 16, 2007. SCCP improved its national NIH funding ranking from 31 to 23 out of ~100 Colleges of Pharmacy.

Recommendation of Administration: That this report be received as information.

Recommendation of Committee: That this report be received as information.

Board Action:

Item 11. Amendments to the Faculty Senate Constitution.

Statement: At the request of the Faculty Senate, administration presented for approval, proposed amendments to the Faculty Senate Constitution, effective February 9, 2007.

Recommendation of Administration: That these proposed amendments be approved.

Recommendation of Committee: That these proposed amendments be approved.

Board Action:

Item 12. Creation of Eminent Scholar Designation

Statement: Administration presented for approval a new faculty designation for highly accomplished faculty members, termed, “Eminent Scholar”, effective February 9, 2007. The idea for this designation is that it could be awarded to individuals whose level of accomplishment is consistent with the award of an endowed chair, but for which no
endowed chair is available. Should an administrative unit at MUSC wish to reward a senior faculty member with this designation, the administration of the department, college and university would need to pledge collectively at least $50,000 per year of support for five years. The funds would be utilized in a manner similar to those traditionally utilized for endowed chair funds. By approving the designation of “Eminent Scholar”, administration would collectively commit to attempting to establish the necessary funds for an endowed chair in the discipline of the Eminent Scholar designee. At the end of five years, the Eminent Scholar designation could be converted to an endowed chair should sufficient funds be available. Alternatively, the Eminent Scholar designation could be renewed for another five years, utilizing guidelines similar to those in place for endowed chair reviews.

Administration believes that this mechanism could address some perceived inequities in the qualifications and levels of accomplishments of endowed chairholders and other senior faculty members who do not hold endowed chairs. Designations as “Eminent Scholar” would be presented to the Board of Trustees as an information item.

Recommendation of Administration: That the proposed “Eminent Scholar” designation be approved.

Recommendation of Committee: That the proposed “Eminent Scholar” designation be approved.

Board Action:

Item 13. Other Committee Business.

A. Quality Enhancement Plan (QEP) for SACS Accreditation

Statement: Administration presented for approval the Quality Enhancement Plan (QEP), which is an essential requirement of the SACS reaffirmation of accreditation process, effective February 8, 2007.

Recommendation of Administration: That the Quality Enhancement Plan (QEP) for SACS Reaffirmation of Accreditation be approved.

Recommendation of Committee: That the Quality Enhancement Plan (QEP) for SACS Reaffirmation of accreditation be approved.

Board Action:
CONSENT AGENDA

Item 14. Faculty Promotions

Statement: At the request of the Chair of the Department of Library Science and Informatics, administration presented for approval the following faculty promotion, effective January 1, 2007.

Margaret P. Schachte, M.B.A., from Assistant Professor to Associate Professor, Department of Library Science and Informatics, effective January 1, 2007.

Recommendation of Administration: That this faculty promotion be approved.

Recommendation of Committee: That this faculty promotion be approved.

Board Action:

Item 15. Faculty Appointments

Statement: At the request of the Deans of the Colleges of Dental Medicine, Medicine, the South Carolina College of Pharmacy, and the College of Nursing, administration presented for approval the following faculty appointments:

**College of Medicine and Dental Medicine**

**Stephen M. Lanier, Ph.D.,** (joint appointment) as Professor with tenure in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics, effective December 1, 2006.

**John S. Markowitz, Pharm.D.,** (joint appointment) as Associate Professor in the Department of Psychiatry and Behavioral Sciences, effective January 1, 2007.

Dr. Markowitz' primary appointment rests in the Department of Pharmaceutical Sciences, College of Pharmacy/SCCP.

**College of Medicine**

**Marie-Florence Shadlen, M.D.,** Clinical Associate Professor, Department of Medicine, Division of General Internal Medicine, effective November 1, 2006.

**MUSC College of Pharmacy / South Carolina College of Pharmacy**

**Philip D. Bell, Ph.D.,** (joint appointment) as Professor in the Department of Pharmaceutical Sciences, effective February 1, 2007.

Dr. Bell’s primary appointment rests in the Department of Medicine, College of Medicine.

**Maurizio Del Poeta, M.D.,** (dual appointment) as Associate Professor in the Department of Medicine, Division of Infectious Disease, effective October 1, 2006.

Dr. Del Poeta’s primary appointment rests in the Department of Biochemistry and Molecular Biology, College of Medicine

**College of Nursing**

**Janis K. Beckstrand, Ph.D., R.N.,** Adjunct Associate professor in the Department of Nursing, effective January 2, 2007.

Recommendation of Administration: That these faculty appointments be approved.

Recommendation of Committee: That these faculty appointments be approved.

Board Action:
Item 16. Changes in Faculty Status

Statement: At the request of the Dean of the College of Medicine, administration presented for approval the follow change in faculty status:

**College of Medicine**

Linda S. Austin, M.D., from Adjunct Professor to Clinical Professor, in the Department of Psychiatry and Behavioral Sciences, effective January 1, 2007.

Recommendation of Administration: That this change in faculty status be approved.

Recommendation of Committee:

Board Action: That this change in faculty status be approved.

(Informational Items)

Item 17: Post-Tenure Review (Information)

Statement: Administration presented as information, the approved Post-Tenure Reviews for the following faculty appointments:

**College of Medicine**

Narendra L. Banik, Ph.D., Professor, Department of Neurosciences
Narayan R. Bhat, Ph.D., Professor, Department of Neurosciences
James A. Cook, Ph.D., Professor, Department of Neurosciences
Craig E. Crosson, Ph.D., Professor, Department of Ophthalmology
Rosalie K. Crouch, Ph.D., Professor, Department of Ophthalmology
Nancy Lynne S. Curry, M.D., Professor, Department of Radiology
David R. Garr, M.D., Professor, Department of Family Medicine
Sebastiano Gattoni-Celli, M.D., Professor, Department of Radiation Oncology
Ann-Charlotte E. Granholm-Bentley, Ph.D., D.D.S., Professor, Department of Neurosciences

Leonie Gordon, M.D., Professor, Department of Radiology
Barry L. Hainer, M.D., Professor, Department of Family Medicine
William J. Hueston, M.D., Professor, Department of Family Medicine
Joseph M. Jenrette, III, M.D., Professor, Department of Radiation Oncology.
Peter W. Kalivas, Ph.D., Professor, Department of Neurosciences
Henry F. Martin, Ph.D., Professor, Department of Neurosciences
Jacqueline F. McGinty, Ph.D., Professor, Department of Neurosciences
Steven M. Ornstein, M.D., Professor, Department of Family Medicine
Richard A. Saunders, M.D., Professor, Department of Ophthalmology
Stephen I. Schabel, M.D., Professor, Department of Radiology
Ronald E. See, Ph.D., Professor, Department of Neurosciences
William M. Simpson, Jr., M.D., Professor, Department of Family Medicine.
M. Edward Wilson, M.D., Professor, Department of Ophthalmology
W. Curtis Wise, Ph.D., Professor, Department of Neurosciences

**College of Nursing**

Gail W. Stuart, Ph.D., Professor, Department of Nursing

Recommendation of Administration: That these approved Post-Tenure Reviews be received as information.

Recommendation of Committee: That these approved Post-Tenure Reviews be received as information.

Board Action:
Item 18: **Eminent Scholar Designation to Robert G. Gourdie, Ph.D.** *(Information)*

**Statement:** At the request of the Dean of the College of Medicine, administration presented as information, the designation of *Eminent Scholar in Developmental Cardiac Biology*, to **Robert G. Gourdie, Ph.D.**, Professor in the Department of Cell Biology and Anatomy, effective January 1, 2007.

**Recommendation of Administration:** That the Eminent Scholar in Developmental Cardiac Biology Designation to Robert G. Gourdie, Ph.D., be received as information.

**Recommendation of Committee:** That the Eminent Scholar in Developmental Cardiac Biology Designation to Robert G. Gourdie, Ph.D., be received as information.

**Board Action:**

Item 19: **Endowed Professor Designations** *(Information)*

**Statement:** At the request of the Dean of the College of Medicine, administration presented as information, the following named Endowed Chairs, effective February 9, 2007.

- **Kerry D. Solomon, M.D.**, as the Arthur and Holly Magill Endowed Chair in Ophthalmology.
- **Gene R. Howard, M.D.**, as the Stanley and Theodora Feldberg Endowed Chair in Ophthalmology.

**Recommendation of Administration:** That these named Endowed Chairs be received as information.

**Recommendation of Committee:** That these named Endowed Chairs be received as information.

**Board Action:**
COMMITTEE ON FINANCE AND ADMINISTRATION
February 8, 2007
Minutes

Attendees:
Mr. Charles Schulze, Chair
Dr. Stanley C. Baker, Jr.
Mr. William H. Bingham, Sr.
Mr. William B. Hewitt
Dr. Thomas C. Rowland, Jr.
Thomas L. Stephenson, Esquire
Dr. James E. Wiseman, Jr.
Dr. Raymond S. Greenberg
Mr. John L. Cooper
Dr. Jack Feussner
Ms. Susan Haskill
Mr. Chip Hood
Mr. Mike Keels
Mr. Stewart Mixon
Ms. Lisa Montgomery
Dr. John Raymond
Dr. Jerry Reves
Ms. Janet Scarborough
Mr. Stuart Smith
Mr. Bruce Quinlan

Mr. Schulze called the meeting to order.

REGULAR Items

Item 20  General Report by the Vice President for Finance and Administration

Ms. Montgomery reported the FY’07-08 budget packages will be distributed this week. She reminded the Committee that they need to review the budget in June and said she would work with Mr. Schulze to get it scheduled at their convenience.

She updated the Committee on the Division of Finance and Administration’s MUSC Excellence program. She attributed the Division’s participation in the program to a marked improvement in employee’s satisfaction with communication from supervisors as shown in a recent employee survey. As employee’s satisfaction with their work environment improves, she believes customer service provided by the Division employees will also improve. Surveys of customer satisfaction will begin in the near future.

Recommendation of Committee: That this report be received as information.

Item 21  Financial Status Report of the Medical University of South Carolina

Ms. Susan Haskill presented the financial status of the University. The cash position is good and, actually, better than it appears since the University has $21 million in state appropriations that it will begin drawing down. Current funds are tracking ahead of last year and that trend is expected to continue until year end. The financial statements show a positive bottom line of $14.8 million.

Recommendation of Committee: That this report be received as information.

Item 22  Financial Status Report of University Medical Associates

Mr. Bruce Quinlan reported UMA revenues of $91 million compared to $78 million during the same period last year. Collections are up 18% and clinical activity is up 13%. As a result of increased activity, expenses are up due mostly to increased faculty compensation. Carolina Family Care revenues are flat. Transfers to the University were $11.2 million for the period ending December 2006 as compared to $8 million during the same time last year.

Recommendation of Committee: That this report be received as information.
**Item 23**  
Financial Status Report of MUSC Foundation for Research Development

Ms. Janet Scarborough reported as of December 31, 2006, the Foundation’s change in net assets is negative $84k. This represents an improvement of $77k since November, 2006.

The improvement is due to:

- The accrual of patent prosecution reimbursement from licensees of costs through October 2006.
- The receipt of $500k from a license for the Singh technology. The Foundation will retain $30k in administrative fee plus approximately $10k in out of pocket costs. The remainder will be distributed to MUSC and inventors and that distribution has been accrued.
- The resolution of the Shrimp Improvement System research and license agreements provides approximately $60k through recovery of bad debt and retainage of license administrative fee.

One item which negatively effected the change in net asset balances is included in the December 2006 statements. This item also related to the Singh technology and is a write off of prior patent prosecution recoveries previously recorded as revenue.

So this change in net assets is actually conservative and, hopefully, will continue to improve in the second half of the year.

**Recommendation of Committee:** That this report be received as information

**Item 24**  
Other Committee Business

Mr. Schulze stated that both the Authority and the University are doing relatively well financially as compared to previous years. It is a positive sign that the Authority has increased days cash on hand and is well ahead of projections of the feasibility study. The University finances look good too.

He asked the committee to think about whether the June budget meeting should be held in Charleston or Columbia.

**CONSENT AGENDA**

**None**

There being no further business, the meeting was adjourned.
Attendees:

Mr. William H. Bingham, Sr., Chair  
Dr. Stanley C. Baker, Jr.  
Mr. Melvyn Berlinsky  
Dr. Cotesworth P. Fishburne, Jr.  
Mr. William B. Hewitt  
Mr. Charles W. Schulze  
Thomas L. Stephenson, Esquire  
Dr. Charles B. Thomas, Jr.  
Dr. James E. Wiseman, Jr.  
Dr. Raymond S. Greenberg  
Mr. John Cooper  
Ms. Annette Drachman  
Dr. Jack Feussner  
Mr. Dennis Frazier  
Mr. Steve Hargett  
Mr. Chris Malanuk  
Mr. John Malmrose  
Mr. Stewart Mixon  
Ms. Jennifer Pearce  
Dr. John Raymond  
Dr. Jerry Reves  
Dean Jack Sanders

Mr. Bingham called the meeting to order.

REGULAR Items

Item 25. Facilities Procurements/Contracts Proposed

Mr. John Malmrose presented the following procurements/contracts for approval:

- College of Nursing Clinical Teaching Lab Construction Project Scope Change: Total estimated budget: $2,500,000.

- Hazardous Weather Upgrades - Phase I fund source change/budget increase: - Total estimated budget $856,000.

- Lease renewal for 75,100 square feet of warehouse space located at 4295 Arco Lane to provide space for University Record Center, Library Archives, Property Control, University Press and Materials Management: Total Cost of five-year lease: $684,000.

- Lease renewal of 2,614 square feet of clinical space located at 57 Bee Street to provide space for MUSC Employee Health Services. Total cost of five year lease: $171,720 with extended option of five years with terms to be negotiated.

- Lease renewal of 7,962 square feet of office space located at 20 Ehrhardt Street for Pharmacy Billing, Department of Radiology, Department of Neurology, HCC, Office of EEOC and Family Medicine. Total cost of five year lease: $261,540 with extended option of five years with terms to be negotiated.
• Lease renewal of 2,242 square feet of office space located at 28 Ehrhardt Street to provide space for the Office of Planning and Special Projects. Total cost of five year lease: $75,180 with extended option of five years with terms to be negotiated.

• Lease renewal of 3,327 square feet of office space located at 45 Bee Street to provide space for Internal Audit. Total cost of five year lease: $98,880 with extended option of five years with terms to be negotiated.

Recommendation of Committee: That the procurements/contracts be approved as presented.

Item 26. Update on Projects

Mr. Malmrose presented an update on various University projects including the College of Dental Medicine, the Bee Street Garage, the Drug Discovery Building, the Pharmacology Lab Renovations, Colcock Hall Parking Lot and the Energy Performance Contract.

Recommendation of Committee: That the report be received as information.

Item 27 Other Committee Business

None

CONSENT Items for Information:

Item 28 Facilities Contracts Awarded

The facilities contracts awarded since the last board meeting were presented for information.

Recommendation of Committee: That this report be received as information.

With no further business, the meeting was adjourned.